WTX-124: "WTX-124 was generally well tolerated as a monotherapy in the outpatient setting"; Cutaneous squamous cell carcinoma (Werewolf Therapeutics) - Dec 3, 2024 - Corporate Presentation: "WTX-124 monotherapy induced rapid, durable regressions of target lesions"
P1 data • Cutaneous Melanoma • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma
|